Shinpoong Pharmaceutical Co Ltd Asset Resilience Ratio
Shinpoong Pharmaceutical Co Ltd asset resilience ratio. Shinpoong Pharmaceutical Co Ltd (019175) has an Asset Resilience Ratio of 6.61% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shinpoong Pharmaceutical Co Ltd (019175) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Shinpoong Pharmaceutical Co Ltd (2014–2025)
Asset resilience ratio of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025. This chart shows how Shinpoong Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Shinpoong Pharmaceutical Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Shinpoong Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Shinpoong Pharmaceutical Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩24.22 Billion | 6.61% |
| Total Liquid Assets | ₩24.22 Billion | 6.61% |
Asset Resilience Insights
- Limited Liquidity: Shinpoong Pharmaceutical Co Ltd maintains only 6.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shinpoong Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shinpoong Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Shinpoong Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2014–2025)
Shinpoong Pharmaceutical Co Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Shinpoong Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.83% | ₩24.07 Billion ≈ $16.31 Million |
₩352.47 Billion ≈ $238.86 Million |
+2.60pp |
| 2024-12-31 | 4.23% | ₩14.47 Billion ≈ $9.81 Million |
₩342.09 Billion ≈ $231.83 Million |
-0.56pp |
| 2023-12-31 | 4.79% | ₩16.78 Billion ≈ $11.37 Million |
₩350.08 Billion ≈ $237.25 Million |
+0.86pp |
| 2022-12-31 | 3.93% | ₩14.23 Billion ≈ $9.64 Million |
₩361.54 Billion ≈ $245.01 Million |
-12.64pp |
| 2021-12-31 | 16.57% | ₩65.07 Billion ≈ $44.09 Million |
₩392.58 Billion ≈ $266.05 Million |
-11.11pp |
| 2020-12-31 | 27.68% | ₩134.84 Billion ≈ $91.38 Million |
₩487.15 Billion ≈ $330.13 Million |
+16.35pp |
| 2019-12-31 | 11.33% | ₩43.07 Billion ≈ $29.19 Million |
₩380.11 Billion ≈ $257.60 Million |
+3.61pp |
| 2018-12-31 | 7.72% | ₩29.42 Billion ≈ $19.94 Million |
₩380.95 Billion ≈ $258.17 Million |
+2.78pp |
| 2017-12-31 | 4.94% | ₩19.06 Billion ≈ $12.91 Million |
₩385.61 Billion ≈ $261.32 Million |
-1.04pp |
| 2016-12-31 | 5.98% | ₩24.90 Billion ≈ $16.88 Million |
₩416.49 Billion ≈ $282.25 Million |
+5.10pp |
| 2015-12-31 | 0.88% | ₩3.62 Billion ≈ $2.45 Million |
₩410.73 Billion ≈ $278.35 Million |
+0.19pp |
| 2014-12-31 | 0.69% | ₩2.84 Billion ≈ $1.93 Million |
₩409.30 Billion ≈ $277.37 Million |
-- |
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more